NKG2D ligand tumor expression and association with clinical outcome in early breast cancer patients: an observational study

de Kruijf, Esther M; Sajet, Anita; van Nes, Johanna GH; Putter, Hein; Smit, Vincent THBM; Eagle, Robert A; Jafferji, Insiya; Trowsdale, John; Liefers, Gerrit Jan; van de Velde, Cornelis JH; Kuppen, Peter JK

doi:10.1186/1471-2407-12-24

Table 1 Correlations between MIC-A-B, ULBP-1, ULBP-2 expression and well-established prognostic factors.

From: NKG2D ligand tumor expression and association with clinical outcome in early breast cancer patients: an observational study

	Total		MICAB				ULBP1				ULBP2
			Low		High		Low		High		Low		High
	N	%	N	%	N	%	N	%	N	%	N	%	N	%
Age
< 40 40-50 50-60 > = 60	48 145 132 249	8.4 25.3 23.0 43.4	4 28 26 42	4.0 28.0 26.0 42.0	31 86 78 163	8.7 24.0 21.8 45.5	22 62 45 91	10.0 28.2 20.5 41.4	10 32 44 79	6.1 19.4 26.7 47.9	34 85 100 172	8.7 21.7 25.6 44.0	9 42 20 52	7.3 34.1 16.3 42.3
Grade
I II III	80 282 203	14.2 49.9 35.9	22 42 36	22.0 42.0 36.0	38 181 131	10.9 51.7 37.4	39 109 68	18.1 50.5 31.5	9 80 74	5.5 49.1 45.4	41 188 155	10.7 49.0 40.4	27 65 30	22.1 53.3 24.6
Histological type
Ductal Lobular	513 53	90.6 9.4	91 9	91.0 9.0	322 29	91.7 8.3	194 22	89.8 10.2	151 12	92.6 7.4	354 30	92.2 7.8	106 16	86.9 13.1
T-status
T1 T2 T3/4	211 272 72	38.0 49.0 13.0	40 44 12	41.7 45.8 12.5	124 176 47	35.7 50.7 13.5	96 87 31	44.9 40.7 14.5	37 96 26	23.3 60.4 16.4	128 198 54	33.7 52.1 14.2	59 46 12	50.4 39.3 10.3
N-status
N0 N1-3	307 250	55.1 44.9	60 38	61.2 38.8	181 162	52.8 47.2	118 97	54.9 45.1	69 86	44.5 55.5	196 183	51.7 48.3	74 45	62.2 37.8
ER-status
Negative Positive	203 337	37.6 62.4	33 65	33.7 66.3	137 212	39.3 60.7	95 122	43.8 56.2	55 103	34.8 65.2	147 238	38.2 61.8	45 75	37.5 62.5
PgR-status
Negative Positive	223 313	41.6 58.4	33 66	33.3 66.7	147 198	42.6 57.4	88 127	40.9 59.1	68 90	43.0 57.0	169 217	43.8 56.2	40 78	33.9 66.1
Her2-status
No overexpression- Overexpression	378 44	89.6 10.4	78 6	92.9 7.1	264 36	88.0 12.0	174 20	89.7 10.3	125 15	89.3 10.7	291 29	90.9 9.1	79 14	84.9 15.1
Local Therapy
MAST-RT MAST+RT BCS-RT BCS+RT	223 108 5 238	38.9 18.8 0.9 41.5	41 17 0 42	41.0 17.0 0.0 42.0	146 66 5 141	40.8 18.4 1.4 39.4	80 46 2 92	36.4 20.9 0.9 41.8	79 33 2 51	47.9 20.0 1.2 30.9	149 83 5 154	38.1 21.2 1.3 39.4	53 15 0 55	43.1 12.2 0.0 44.7
Systemic therapy
CT alone HT alone CT&HT None	112 75 18 369	19.5 13.1 3.1 64.3	17 8 1 74	17.0 8.0 1.0 74.0	73 54 13 218	20.4 15.1 3.6 60.9	44 31 3 142	20.0 14.1 1.4 64.5	25 29 9 102	15.2 17.6 5.5 61.8	80 54 14 243	20.5 13.8 3.6 62.1	24 16 3 80	19.5 13.0 2.4 65.0
Total	574	100	100	100	358	100	220	100	165	100	391	100	123	100

Missing values are not shown.
AbbreviationsN number of patients; % percentage; ER estrogen receptor; PgR progesterone receptor; HER2 human epidermal growth factor receptor 2; MAST mastectomy; RT radiotherapy; BCS breast conservative surgery; ET endocrine therapy; CT chemotherapy.

Back to article page

ISSN: 1471-2407

Contact us

Submission enquiries: bmccancer@biomedcentral.com
General enquiries: ORSupport@springernature.com

BMC Cancer

Contact us